Education
About Us
Working with TipRanks
Follow Us
Vitrolife AB (SE:VITR)
:VITR
VITR Stock Chart & Stats
kr133.00
-kr3.40(-1.91%)
At close: 4:00 PM EST
kr133.00
-kr3.40(-1.91%)
Day’s Range― - ―
52-Week Rangekr84.90 - kr215.20
Previous CloseN/A
Volume81.91K
Average Volume (3M)92.36K
Market Cap
kr11.96B
Enterprise Valuekr13.14B
Total Cash (Recent Filing)kr809.00M
Total Debt (Recent Filing)kr1.68B
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Apr 23, 2026EPS Estimate
0.82Next Dividend Ex-DateN/A
Dividend Yield0.8%
Share Statistics
EPS (TTM)0.66
Shares Outstanding135,447,190
10 Day Avg. Volume105,869
30 Day Avg. Volume92,365
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.35
Price to Sales (P/S)5.39
P/FCF Ratio50.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market Position & Product BreadthA broad, clinic-essential product portfolio (culture media, cryopreservation, equipment and training) creates recurring consumables demand and multiple touchpoints with customers. That durable commercial footprint supports steady replacement/consumable revenue and cross-sell opportunities across clinics worldwide.
Technologies MomentumRapid adoption of higher‑value Technologies (EmbryoScope) indicates successful product-market fit and commercial execution. Growing installed base and penetration boost higher‑margin sales, enable cross-selling of consumables, and create a structural lever for future margin recovery as penetration expands.
Balance Sheet & Cash GenerationManageable leverage and positive operating/free cash flow provide financing flexibility to fund R&D, commercial expansion and restructuring while maintaining shareholder returns. This cash generation cushions shocks and supports strategic initiatives during the recovery period.
Bears Say
Earnings VolatilityA dramatic swing to a large loss signals weak earnings quality and high volatility in profitability. Such swings erode equity, reduce management flexibility, and make multi-period planning harder; normalization may take multiple quarters and depend on execution and external FX trends.
Margin Pressure & MixMaterial margin deterioration driven by mix, higher OpEx and restructuring undermines sustainable profitability. If mix shifts toward lower‑margin disposables or restructuring/outsource effects persist, recovering prior margin levels will require sustained product mix improvement and cost leverage.
Weakened Cash ConversionSignificant declines in operating and free cash flow reduce the company's buffer for reinvestment and restructuring. Slower cash conversion increases reliance on precise working capital management and could constrain discretionary spending or delay margin‑restoring investments.
Vitrolife AB News
VITR FAQ
What was Vitrolife AB’s price range in the past 12 months?
Vitrolife AB lowest stock price was kr84.90 and its highest was kr215.20 in the past 12 months.
What is Vitrolife AB’s market cap?
Vitrolife AB’s market cap is kr11.96B.
When is Vitrolife AB’s upcoming earnings report date?
Vitrolife AB’s upcoming earnings report date is Apr 23, 2026 which is in 61 days.
How were Vitrolife AB’s earnings last quarter?
Vitrolife AB released its earnings results on Feb 03, 2026. The company reported kr0.66 earnings per share for the quarter, beating the consensus estimate of -kr12.34 by kr13.
Is Vitrolife AB overvalued?
According to Wall Street analysts Vitrolife AB’s price is currently Overvalued.
Does Vitrolife AB pay dividends?
Vitrolife AB pays a Annually dividend of kr1.1 which represents an annual dividend yield of 0.8%. See more information on Vitrolife AB dividends here
What is Vitrolife AB’s EPS estimate?
Vitrolife AB’s EPS estimate is 0.82.
How many shares outstanding does Vitrolife AB have?
Vitrolife AB has 135,447,190 shares outstanding.
What happened to Vitrolife AB’s price movement after its last earnings report?
Vitrolife AB reported an EPS of kr0.66 in its last earnings report, beating expectations of -kr12.34. Following the earnings report the stock price went down -21.52%.
Which hedge fund is a major shareholder of Vitrolife AB?
Currently, no hedge funds are holding shares in SE:VITR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vitrolife AB
Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It provides oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; incubators; cryopreservation; and preimplantation genetic testing products. The company also offers EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; evaluation tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems and wireless sensors. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; and North and South America. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1994 and is headquartered in Gothenburg, Sweden.
Technical Analysis
Getinge
―
BICO Group AB Class B
―
CellaVision AB
―
Xvivo Perfusion AB
―
Sectra AB Class B
―
Options Prices
Currently, No data available
---